Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Updates from the MonumenTAL-1 trial

Monique Minnema • 11 Jun 2022
EHA 2022
Multiple Myeloma Antibodies Talquetamab Tocilizumab
MonumenTAL-1

Monique Minnema, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands, shares some updates from the Phase I MonumenTAL-1 trial (NCT04634552) evaluating the safety and efficacy of talquetamab at two recommended doses in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Monique Minnema

0:54
The importance of genomics-based stratification in multiple myeloma
Monique Minnema • 11 Jun 2022
1:20
A comparison of bispecific antibodies emerging in multiple myeloma
Monique Minnema • 11 Jun 2022
1:37
Patient education in CAR T-cell therapy
Monique Minnema • 20 Mar 2019
1:58
The logistical challenges of CAR T-cell therapy
Monique Minnema • 20 Mar 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals